Protein Supplementation and Muscle Function in the Elderly
NCT ID: NCT03815201
Last Updated: 2019-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
41 participants
INTERVENTIONAL
2017-10-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of the current study is to determine if leucine-enriched protein ingestion after exercise training helps to increase muscle mass gains. Secondary outcomes will be to analyse the different effects among cognitive performance, depressive symptoms, disability, inflammation, quality of life and use of healthcare services.
A randomized controlled trial will be carried out to assess the objectives of the current study. Participants will be randomized into two different groups (N=40, each one): an exercise training control group and exercise training plus leucine-enriched protein ingestion intervention group. Exercise training will take 12 weeks of supervised training intervention and 12 weeks of non-supervised training intervention for both groups. Biological samples will be analysed in Biodonostia Health Research Institute and in the University of the Basque Country (UPV/EHU).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protein Supplementation and Mixed Power Training on Muscle Function and Functional Capacities in Elderly Men
NCT03393650
A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People
NCT01110369
Protein Intake and Resistance Training in Aging
NCT01890382
Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program
NCT03417531
The Effects of Resistance Training and Protein Supplementation in Healthy Elderly Men and Women.
NCT01004588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A week after discharge day, patients will again be evaluated (Laboratory 1 (Lab 1) evaluation day): the same tests of discharge day will be repeated plus Berg Scale and 6-Minute Walking Test. Then, patients will wait until a group of 5-6 participants is formed. As soon as patients accept to participate, and when all evaluation tests involved until Lab 1 evaluation day are completed, participants will be randomized into two different groups: exercise training plus placebo control group (Group 1) and exercise training plus leucine-enriched protein ingestion intervention group (Group 2).
Participants will be called by telephone a week before the intervention starts for psychological assessment, blood analysis and Dual Energy X-ray Absorptiometry (DEXA) assessment.
The first day of intervention program all participants will be evaluated for nutritional assessment: Mini Nutritional Assessment (MNA) Test, a quantitative score (14-item) of adherence to the Mediterranean diet (Prevention with Mediterranean Diet (PREDIMED) questionnaire), two non-consecutive 24-hour dietary recall and anthropometry.
Exercise training intervention will be divided into supervised intervention and non-supervised intervention for both groups. Supervised intervention program will take 12 weeks and participants will have to assist 2 non-consecutive days per week to hospital for 1-hour exercise training. After those 12 weeks participants will take two accelerometers, a wrist accelerometer and a hip accelerometer, for a week. After that week participants will have to assist 2 non-consecutive days on the same week to complete: the same physical tests of Lab 1 evaluation day, anthropometry and nutritional tests, blood analysis and DEXA assessment. Individualised physical exercise recommendations will be explained and given to participants for the following 12 weeks of non-supervised intervention. During those weeks of non-supervised intervention, telephone monitoring will be made every two weeks.
When completing the study, at week 24, participants will be called by telephone to come to hospital for blood analysis, psychological assessment, nutritional tests and one 24-hour dietary recall, and to take the two accelerometers for a week. After a week, participants will be evaluated for physical assessment (the same physical tests of Lab 1 evaluation day will be carried out) and a second 24-hour dietary recall and anthropometry will be assessed.
The placebo and leucine-enriched protein supplementation will only be taken during supervised training period twice a week after 1-hour exercise training is completed. Participants will ignore what the supplement is, as the mixtures will be codified.
Protein supplementation will consist on 20gr of whey protein (a commercial preparation of Davisco®: BiPRO all-natural whey protein isolate) enriched with 3g of leucine (commercially prepared by Nutricia), and protein mixture will be diluted with 100ml of water. The placebo will be an energy-matched mixture.
The samples will be store at the Basque Biobank and then will be send to Biodonostia Health Research Institute for their analysis.
Sample size: power calculation has been done for the main variable: muscle mass increase. If 35 people are recruited on each group, a difference of unless 1.5 to 2kg will be detected in muscle mass with a standard deviation of 1.5-1.7kg and \>80% of power, and an alfa level of 0.05. Taking into account that mortality can be about 30%, 40 participants will be recruited for each group.
Statistical analysis: variance analysis will be used to analyse the continuous variables and the Chi-square test for the categorical variables, both analyses will be used for the cross-cutting analysis. To evaluate the training effect on the primary and secondary variables general linear models will be used. Age and the pre-intervention value of any primary or secondary variable will be considered as covariates. The effect size and the statistical significance level for each of these effects will be calculated: group effect (between subjects), time effect (intra-subjects) and group\*time interaction. Other possible interactions between group\*sex and all other variables of the study will be determined. The analyses will be adjusted by multiple comparison test and the intend to treat principle will be applied for all analyses. For the analysis of missing data, such as for the participants that drop out from the program or did not meet the study criteria, different imputation methods will be used, and sensitivity analysis will be applied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
Group 1
placebo, an energy-matched mixture, during the first 1/2 hour post-training
Group 2
exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
Group 2
leucine-enriched protein supplementation during the first 1/2 hour post-training
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group 2
leucine-enriched protein supplementation during the first 1/2 hour post-training
Group 1
placebo, an energy-matched mixture, during the first 1/2 hour post-training
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Punctuation at the Mini Mental State Questionnaire (MMSE): \> or = 20.
* Any patient that fulfill the European Working Group on Sarcopenia in Older People (EWGSOP) criteria for sarcopenia diagnosis.
* Anyone who is able to walk alone, to walk using a walking stick or a walking frame, or to walk using parallel walking bars.
* Anyone able to understand the instructions or what is being said.
* Anyone signing the informed consent.
Exclusion Criteria
* To have suffered a heart attack in the last 3 months.
* To be unable to walk.
* To have suffered any fracture of the upper or lower limbs in the last 3 months.
* Anyone suffering from severe dementia.
* Autoimmune neuromuscular disorders (for example, myasthenia gravis, Guillain-Barré syndrome, inflammatory myopathies) or amyotrophic lateral sclerosis.
* Anyone refusing to sign the informed consent, or anyone who does not agree to the study protocol.
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of the Basque Country (UPV/EHU)
OTHER
Hospital Universitario de Álava
OTHER
Basque Health Service
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ariadna Besga
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ariadna Besga
Role: PRINCIPAL_INVESTIGATOR
Basque Health Service
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Santiago Apostol
Vitoria-Gasteiz, Alava, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BasqueHS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.